Regeneron: Q1 adjusted EPS down 4%

(CercleFinance.com) - Regeneron reports Q1 sales of $3,145m, down 1% y-o-y.


The US biotech company reported adjusted net income (non-GAAP) of $1,116m, down 4%.

While investing in innovation remains our top capital allocation priority, the recent authorization by Regeneron's Board of Directors of a new $3bn share repurchase program provides us with additional flexibility to continue returning capital to shareholders over time, it said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.